P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONSMAX-ISO-POLY-3 P
63
F1_Rev.1_R2 NTP Study Number: C20209 Lock Date: 12/07/2005 Cage Range: ALL Date Range: ALL Reasons For Removal: ALL Removal Date Range: ALL Treatment Groups: Include ALL Study Gender: Both TDMSE Version: 3.0.2.0_001 PWG Approval Date: NONE Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014 Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07 Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04 Species/Strain: RATS/F 344/N Lab: SRI
Transcript of P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONSMAX-ISO-POLY-3 P
F1_Rev.1_R2NTP Study Number: C20209
Lock Date: 12/07/2005
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 3.0.2.0_001
PWG Approval Date: NONE
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
MALE RATS
Organ MorphologyEpididymis HypospermiaHeart CardiomyopathyLiver: Hepatocyte Hypertrophy
Vacuolization CytoplasmicLung Inflammation ChronicLung: Alveolar Epithelium HyperplasiaStomach, Glandular ErosionThyroid Gland: Follicle Hypertrophy
FEMALE RATS
Organ MorphologyEye Developmental MalformationLiver Basophilic FocusLiver: Hepatocyte Hypertrophy
Vacuolization CytoplasmicLung Inflammation ChronicStomach, Glandular ErosionThymus AtrophyThyroid Gland: Follicle Hypertrophy
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF PENTABROMODIPHENYL OXIDE (TECHNICAL) (DE 71)
Page 2
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Adrenal CortexAccessory Adrenal Cortical Nodule
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/2 (0%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/0.00 0/0.00 0/2.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/2 (0%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 3
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Bone MarrowHyperplasia
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 2/10 (20%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/0.00 0/0.00 0/0.00 2/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 20%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 2/10 (20%)
FIRST INCIDENCE --- --- --- --- --- 93 (T)
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) P=0.227
POLY 1.5 (e) (e) (e) (e) (e) P=0.227
POLY 6 (e) (e) (e) (e) (e) P=0.227
COCH-ARM / FISHERS P=0.186 (e) (e) (e) (e) P=0.237
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) P=0.066
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 4
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
EpididymisHypospermia
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 9/10 (90%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00 9/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 90%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 9/10 (90%)
FIRST INCIDENCE --- --- --- --- --- 93 (T)
STATISTICAL TESTS
POLY 3 P<0.001** (e) (e) (e) (e) P<0.001**
POLY 1.5 P<0.001** (e) (e) (e) (e) P<0.001**
POLY 6 P<0.001** (e) (e) (e) (e) P<0.001**
COCH-ARM / FISHERS P<0.001** (e) (e) (e) (e) P<0.001**
MAX-ISO-POLY-3 P<0.001** (e) (e) (e) (e) P<0.001**
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 5
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
EyeDevelopmental Malformation
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/0.00 0/0.00 0/0.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 6
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Harderian GlandInflammation Chronic
LESION RATES
OVERALL (a) 1/10 (10%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
POLY-3 RATE (b) 1/10.00 0/0.00 0/0.00 0/0.00 0/0.00 0/10.00
POLY-3 PERCENT (g) 10% 0% 0% 0% 0% 0%
TERMINAL (d) 1/10 (10%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
FIRST INCIDENCE 93 (T) --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) P=0.500N
POLY 1.5 (e) (e) (e) (e) (e) P=0.500N
POLY 6 (e) (e) (e) (e) (e) P=0.500N
COCH-ARM / FISHERS P=0.419N (e) (e) (e) (e) P=0.500N
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) P=0.158N
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 7
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
HeartCardiomyopathy
LESION RATES
OVERALL (a) 3/10 (30%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
POLY-3 RATE (b) 3/10.00 0/0.00 0/0.00 0/0.00 0/0.00 0/10.00
POLY-3 PERCENT (g) 30% 0% 0% 0% 0% 0%
TERMINAL (d) 3/10 (30%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
FIRST INCIDENCE 93 (T) --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) P=0.095N
POLY 1.5 (e) (e) (e) (e) (e) P=0.095N
POLY 6 (e) (e) (e) (e) (e) P=0.095N
COCH-ARM / FISHERS P=0.084N (e) (e) (e) (e) P=0.105N
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) P=0.025N*
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 8
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
KidneyInfiltration Cellular Mononuclear Cell
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/0.00 0/0.00 0/0.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 9
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
KidneyNephropathy
LESION RATES
OVERALL (a) 1/10 (10%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 2/10 (20%)
POLY-3 RATE (b) 1/10.00 0/0.00 0/0.00 0/0.00 0/0.00 2/10.00
POLY-3 PERCENT (g) 10% 0% 0% 0% 0% 20%
TERMINAL (d) 1/10 (10%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 2/10 (20%)
FIRST INCIDENCE 93 (T) --- --- --- --- 93 (T)
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) P=0.500
POLY 1.5 (e) (e) (e) (e) (e) P=0.500
POLY 6 (e) (e) (e) (e) (e) P=0.500
COCH-ARM / FISHERS P=0.450 (e) (e) (e) (e) P=0.500
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) P=0.274
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 10
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
LiverBasophilic Focus
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 11
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
LiverHepatodiaphragmatic Nodule
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 1/10 (10%) 1/10 (10%) 0/10 (0%) 1/10 (10%)
POLY-3 RATE (b) 0/10.00 0/10.00 1/10.00 1/10.00 0/10.00 1/10.00
POLY-3 PERCENT (g) 0% 0% 10% 10% 0% 10%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 1/10 (10%) 1/10 (10%) 0/10 (0%) 1/10 (10%)
FIRST INCIDENCE --- --- 93 (T) 93 (T) --- 93 (T)
STATISTICAL TESTS
POLY 3 P=0.465 (e) P=0.500 P=0.500 (e) P=0.500
POLY 1.5 P=0.465 (e) P=0.500 P=0.500 (e) P=0.500
POLY 6 P=0.465 (e) P=0.500 P=0.500 (e) P=0.500
COCH-ARM / FISHERS P=0.464 (e) P=0.500 P=0.500 (e) P=0.500
MAX-ISO-POLY-3 P=0.158 (e) P=0.158 P=0.158 (e) P=0.158
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 12
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
LiverNecrosis Focal
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 2/10 (20%) 1/10 (10%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 1/10.00 2/10.00 1/10.00
POLY-3 PERCENT (g) 0% 0% 0% 10% 20% 10%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 2/10 (20%) 1/10 (10%)
FIRST INCIDENCE --- --- --- 93 (T) 93 (T) 93 (T)
STATISTICAL TESTS
POLY 3 P=0.372 (e) (e) P=0.500 P=0.227 P=0.500
POLY 1.5 P=0.372 (e) (e) P=0.500 P=0.227 P=0.500
POLY 6 P=0.372 (e) (e) P=0.500 P=0.227 P=0.500
COCH-ARM / FISHERS P=0.371 (e) (e) P=0.500 P=0.237 P=0.500
MAX-ISO-POLY-3 P=0.090 (e) (e) P=0.158 P=0.066 P=0.158
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 13
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Liver: HepatocyteHypertrophy
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 9/10 (90%) 10/10 (100%) 10/10 (100%) 10/10 (100%)
POLY-3 RATE (b) 0/10.00 0/10.00 9/10.00 10/10.00 10/10.00 10/10.00
POLY-3 PERCENT (g) 0% 0% 90% 100% 100% 100%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 9/10 (90%) 10/10 (100%) 10/10 (100%) 10/10 (100%)
FIRST INCIDENCE --- --- 93 (T) 93 (T) 93 (T) 93 (T)
STATISTICAL TESTS
POLY 3 P<0.001** (e) P<0.001** P<0.001** P<0.001** P<0.001**
POLY 1.5 P<0.001** (e) P<0.001** P<0.001** P<0.001** P<0.001**
POLY 6 P<0.001** (e) P<0.001** P<0.001** P<0.001** P<0.001**
COCH-ARM / FISHERS P<0.001** (e) P<0.001** P<0.001** P<0.001** P<0.001**
MAX-ISO-POLY-3 P<0.001** (e) P<0.001** (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 14
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Liver: HepatocyteVacuolization Cytoplasmic
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 10/10 (100%) 10/10 (100%) 10/10 (100%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 10/10.00 10/10.00 10/10.00
POLY-3 PERCENT (g) 0% 0% 0% 100% 100% 100%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 10/10 (100%) 10/10 (100%) 10/10 (100%)
FIRST INCIDENCE --- --- --- 93 (T) 93 (T) 93 (T)
STATISTICAL TESTS
POLY 3 P<0.001** (e) (e) P<0.001** P<0.001** P<0.001**
POLY 1.5 P<0.001** (e) (e) P<0.001** P<0.001** P<0.001**
POLY 6 P<0.001** (e) (e) P<0.001** P<0.001** P<0.001**
COCH-ARM / FISHERS P<0.001** (e) (e) P<0.001** P<0.001** P<0.001**
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 15
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
LungHemorrhage
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 1/10.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 10% 0%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- 93 (T) ---
STATISTICAL TESTS
POLY 3 P=0.858N (e) (e) (e) P=0.500 (e)
POLY 1.5 P=0.858N (e) (e) (e) P=0.500 (e)
POLY 6 P=0.858N (e) (e) (e) P=0.500 (e)
COCH-ARM / FISHERS P=0.860N (e) (e) (e) P=0.500 (e)
MAX-ISO-POLY-3 P=0.193 (e) (e) (e) P=0.158 (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 16
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
LungInfiltration Cellular Histiocyte
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 1/10 (10%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 1/10.00 1/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 10% 10%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 1/10 (10%)
FIRST INCIDENCE --- --- --- --- 93 (T) 93 (T)
STATISTICAL TESTS
POLY 3 P=0.236 (e) (e) (e) P=0.500 P=0.500
POLY 1.5 P=0.236 (e) (e) (e) P=0.500 P=0.500
POLY 6 P=0.236 (e) (e) (e) P=0.500 P=0.500
COCH-ARM / FISHERS P=0.232 (e) (e) (e) P=0.500 P=0.500
MAX-ISO-POLY-3 P=0.109 (e) (e) (e) P=0.158 P=0.158
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 17
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
LungInflammation Chronic
LESION RATES
OVERALL (a) 2/10 (20%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%)
POLY-3 RATE (b) 2/10.00 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00
POLY-3 PERCENT (g) 20% 0% 0% 0% 0% 0%
TERMINAL (d) 2/10 (20%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%)
FIRST INCIDENCE 93 (T) --- --- --- --- ---
STATISTICAL TESTS
POLY 3 P=0.469N P=0.227N P=0.227N P=0.227N P=0.227N P=0.227N
POLY 1.5 P=0.469N P=0.227N P=0.227N P=0.227N P=0.227N P=0.227N
POLY 6 P=0.469N P=0.227N P=0.227N P=0.227N P=0.227N P=0.227N
COCH-ARM / FISHERS P=0.471N P=0.237N P=0.237N P=0.237N P=0.237N P=0.237N
MAX-ISO-POLY-3 P=0.005N** P=0.066N P=0.066N P=0.066N P=0.066N P=0.066N
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 18
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Lung: Alveolar EpitheliumHyperplasia
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00 1/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 10%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%)
FIRST INCIDENCE --- --- --- --- --- 93 (T)
STATISTICAL TESTS
POLY 3 P=0.142 (e) (e) (e) (e) P=0.500
POLY 1.5 P=0.142 (e) (e) (e) (e) P=0.500
POLY 6 P=0.142 (e) (e) (e) (e) P=0.500
COCH-ARM / FISHERS P=0.140 (e) (e) (e) (e) P=0.500
MAX-ISO-POLY-3 P=0.041* (e) (e) (e) (e) P=0.158
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 19
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Lymph Node: MediastinalHemorrhage
LESION RATES
OVERALL (a) 0/0 (0%) 0/1 (0%) 0/0 (0%) 1/1 (100%) 1/1 (100%) 0/0 (0%)
POLY-3 RATE (b) 0/0.00 0/1.00 0/0.00 1/1.00 1/1.00 0/0.00
POLY-3 PERCENT (g) 0% 0% 0% 100% 100% 0%
TERMINAL (d) 0/0 (0%) 0/1 (0%) 0/0 (0%) 1/1 (100%) 1/1 (100%) 0/0 (0%)
FIRST INCIDENCE --- --- --- 93 (T) 93 (T) ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) (e)
POLY 1.5 (e) (e) (e) (e) (e) (e)
POLY 6 (e) (e) (e) (e) (e) (e)
COCH-ARM / FISHERS P=1.000 (e) (e) (e) (e) (e)
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 20
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Lymph Node: MediastinalHyperplasia Lymphoid
LESION RATES
OVERALL (a) 0/0 (0%) 0/1 (0%) 0/0 (0%) 1/1 (100%) 1/1 (100%) 0/0 (0%)
POLY-3 RATE (b) 0/0.00 0/1.00 0/0.00 1/1.00 1/1.00 0/0.00
POLY-3 PERCENT (g) 0% 0% 0% 100% 100% 0%
TERMINAL (d) 0/0 (0%) 0/1 (0%) 0/0 (0%) 1/1 (100%) 1/1 (100%) 0/0 (0%)
FIRST INCIDENCE --- --- --- 93 (T) 93 (T) ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) (e)
POLY 1.5 (e) (e) (e) (e) (e) (e)
POLY 6 (e) (e) (e) (e) (e) (e)
COCH-ARM / FISHERS P=1.000 (e) (e) (e) (e) (e)
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 21
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Lymph Node: PancreaticHemorrhage
LESION RATES
OVERALL (a) 0/0 (0%) 1/1 (100%) 0/0 (0%) 0/1 (0%) 0/1 (0%) 0/0 (0%)
POLY-3 RATE (b) 0/0.00 1/1.00 0/0.00 0/1.00 0/1.00 0/0.00
POLY-3 PERCENT (g) 0% 100% 0% 0% 0% 0%
TERMINAL (d) 0/0 (0%) 1/1 (100%) 0/0 (0%) 0/1 (0%) 0/1 (0%) 0/0 (0%)
FIRST INCIDENCE --- 93 (T) --- --- --- ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) (e)
POLY 1.5 (e) (e) (e) (e) (e) (e)
POLY 6 (e) (e) (e) (e) (e) (e)
COCH-ARM / FISHERS P=1.000N (e) (e) (e) (e) (e)
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 22
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Lymph Node: PancreaticHyperplasia Lymphoid
LESION RATES
OVERALL (a) 0/0 (0%) 1/1 (100%) 0/0 (0%) 0/1 (0%) 0/1 (0%) 0/0 (0%)
POLY-3 RATE (b) 0/0.00 1/1.00 0/0.00 0/1.00 0/1.00 0/0.00
POLY-3 PERCENT (g) 0% 100% 0% 0% 0% 0%
TERMINAL (d) 0/0 (0%) 1/1 (100%) 0/0 (0%) 0/1 (0%) 0/1 (0%) 0/0 (0%)
FIRST INCIDENCE --- 93 (T) --- --- --- ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) (e)
POLY 1.5 (e) (e) (e) (e) (e) (e)
POLY 6 (e) (e) (e) (e) (e) (e)
COCH-ARM / FISHERS P=1.000N (e) (e) (e) (e) (e)
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 23
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Lymph Node: PancreaticPigmentation
LESION RATES
OVERALL (a) 0/0 (0%) 0/1 (0%) 0/0 (0%) 0/1 (0%) 0/1 (0%) 0/0 (0%)
POLY-3 RATE (b) 0/0.00 0/1.00 0/0.00 0/1.00 0/1.00 0/0.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/0 (0%) 0/1 (0%) 0/0 (0%) 0/1 (0%) 0/1 (0%) 0/0 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 24
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Mesentery: FatNecrosis
LESION RATES
OVERALL (a) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%)
POLY-3 RATE (b) 0/0.00 0/0.00 0/0.00 0/0.00 0/0.00 0/0.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 25
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Pituitary Gland: Pars DistalisCyst
LESION RATES
OVERALL (a) 1/10 (10%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
POLY-3 RATE (b) 1/10.00 0/0.00 0/0.00 0/0.00 0/0.00 0/10.00
POLY-3 PERCENT (g) 10% 0% 0% 0% 0% 0%
TERMINAL (d) 1/10 (10%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
FIRST INCIDENCE 93 (T) --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) P=0.500N
POLY 1.5 (e) (e) (e) (e) (e) P=0.500N
POLY 6 (e) (e) (e) (e) (e) P=0.500N
COCH-ARM / FISHERS P=0.419N (e) (e) (e) (e) P=0.500N
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) P=0.158N
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 26
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Salivary GlandsNecrosis
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 1/10 (10%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/0.00 0/0.00 0/0.00 1/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 10%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 1/10 (10%)
FIRST INCIDENCE --- --- --- --- --- 93 (T)
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) P=0.500
POLY 1.5 (e) (e) (e) (e) (e) P=0.500
POLY 6 (e) (e) (e) (e) (e) P=0.500
COCH-ARM / FISHERS P=0.419 (e) (e) (e) (e) P=0.500
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) P=0.158
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 27
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Stomach, GlandularErosion
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 1/10 (10%) 2/10 (20%) 3/10 (30%) 4/10 (40%)
POLY-3 RATE (b) 0/10.00 0/10.00 1/10.00 2/10.00 3/10.00 4/10.00
POLY-3 PERCENT (g) 0% 0% 10% 20% 30% 40%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 1/10 (10%) 2/10 (20%) 3/10 (30%) 4/10 (40%)
FIRST INCIDENCE --- --- 93 (T) 93 (T) 93 (T) 93 (T)
STATISTICAL TESTS
POLY 3 P=0.013* (e) P=0.500 P=0.227 P=0.095 P=0.033*
POLY 1.5 P=0.013* (e) P=0.500 P=0.227 P=0.095 P=0.033*
POLY 6 P=0.013* (e) P=0.500 P=0.227 P=0.095 P=0.033*
COCH-ARM / FISHERS P=0.015* (e) P=0.500 P=0.237 P=0.105 P=0.043*
MAX-ISO-POLY-3 P=0.006** (e) P=0.158 P=0.066 P=0.025* P=0.007**
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 28
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Stomach, Glandular: GlandsDilatation
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 29
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
ThymusAtrophy
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/9 (0%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00 0/9.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/9 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 30
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
ThymusHemorrhage
LESION RATES
OVERALL (a) 1/10 (10%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/9 (0%)
POLY-3 RATE (b) 1/10.00 0/10.00 0/10.00 0/10.00 1/10.00 0/9.00
POLY-3 PERCENT (g) 10% 0% 0% 0% 10% 0%
TERMINAL (d) 1/10 (10%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/9 (0%)
FIRST INCIDENCE 93 (T) --- --- --- 93 (T) ---
STATISTICAL TESTS
POLY 3 P=0.651N P=0.500N P=0.500N P=0.500N P=0.760 P=0.521N
POLY 1.5 P=0.651N P=0.500N P=0.500N P=0.500N P=0.760 P=0.521N
POLY 6 P=0.651N P=0.500N P=0.500N P=0.500N P=0.760 P=0.521N
COCH-ARM / FISHERS P=0.654N P=0.500N P=0.500N P=0.500N P=0.763N P=0.526N
MAX-ISO-POLY-3 P=0.124N P=0.158N P=0.158N P=0.158N P=1.000 P=0.178N
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 31
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Thyroid Gland: FollicleHypertrophy
LESION RATES
OVERALL (a) 0/10 (0%) 0/9 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 9/10 (90%)
POLY-3 RATE (b) 0/10.00 0/9.00 0/10.00 0/10.00 1/10.00 9/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 10% 90%
TERMINAL (d) 0/10 (0%) 0/9 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 9/10 (90%)
FIRST INCIDENCE --- --- --- --- 93 (T) 93 (T)
STATISTICAL TESTS
POLY 3 P<0.001** (e) (e) (e) P=0.500 P<0.001**
POLY 1.5 P<0.001** (e) (e) (e) P=0.500 P<0.001**
POLY 6 P<0.001** (e) (e) (e) P=0.500 P<0.001**
COCH-ARM / FISHERS P<0.001** (e) (e) (e) P=0.500 P<0.001**
MAX-ISO-POLY-3 P<0.001** (e) (e) (e) P=0.158 P<0.001**
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Males
Page 32
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Adrenal CortexAccessory Adrenal Cortical Nodule
LESION RATES
OVERALL (a) 1/10 (10%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
POLY-3 RATE (b) 1/10.00 0/0.00 0/0.00 0/0.00 0/0.00 0/10.00
POLY-3 PERCENT (g) 10% 0% 0% 0% 0% 0%
TERMINAL (d) 1/10 (10%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
FIRST INCIDENCE 93 (T) --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) P=0.500N
POLY 1.5 (e) (e) (e) (e) (e) P=0.500N
POLY 6 (e) (e) (e) (e) (e) P=0.500N
COCH-ARM / FISHERS P=0.419N (e) (e) (e) (e) P=0.500N
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) P=0.158N
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 33
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Bone MarrowHyperplasia
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/0.00 0/0.00 0/0.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 34
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Clitoral GlandInflammation Chronic
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 2/10 (20%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/0.00 0/0.00 0/0.00 2/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 20%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 2/10 (20%)
FIRST INCIDENCE --- --- --- --- --- 93 (T)
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) P=0.227
POLY 1.5 (e) (e) (e) (e) (e) P=0.227
POLY 6 (e) (e) (e) (e) (e) P=0.227
COCH-ARM / FISHERS P=0.186 (e) (e) (e) (e) P=0.237
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) P=0.066
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 35
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
EyeDevelopmental Malformation
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 1/1 (100%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/0.00 0/0.00 1/1.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 100% 0%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 1/1 (100%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- 93 (T) ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) P=0.091 (e)
POLY 1.5 (e) (e) (e) (e) P=0.091 (e)
POLY 6 (e) (e) (e) (e) P=0.091 (e)
COCH-ARM / FISHERS P=0.594N (e) (e) (e) P=0.091 (e)
MAX-ISO-POLY-3 (e) (e) (e) (e) P<0.001** (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 36
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Harderian GlandInflammation Chronic
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/0.00 0/0.00 0/0.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 37
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
HeartCardiomyopathy
LESION RATES
OVERALL (a) 1/10 (10%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
POLY-3 RATE (b) 1/10.00 0/0.00 0/0.00 0/0.00 0/0.00 0/10.00
POLY-3 PERCENT (g) 10% 0% 0% 0% 0% 0%
TERMINAL (d) 1/10 (10%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
FIRST INCIDENCE 93 (T) --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) P=0.500N
POLY 1.5 (e) (e) (e) (e) (e) P=0.500N
POLY 6 (e) (e) (e) (e) (e) P=0.500N
COCH-ARM / FISHERS P=0.419N (e) (e) (e) (e) P=0.500N
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) P=0.158N
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 38
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
KidneyInfiltration Cellular Mononuclear Cell
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 1/10 (10%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/0.00 0/0.00 0/0.00 1/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 10%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 1/10 (10%)
FIRST INCIDENCE --- --- --- --- --- 93 (T)
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) P=0.500
POLY 1.5 (e) (e) (e) (e) (e) P=0.500
POLY 6 (e) (e) (e) (e) (e) P=0.500
COCH-ARM / FISHERS P=0.419 (e) (e) (e) (e) P=0.500
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) P=0.158
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 39
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
KidneyNephropathy
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/0.00 0/0.00 0/0.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 40
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
LiverBasophilic Focus
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00 1/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 10%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%)
FIRST INCIDENCE --- --- --- --- --- 93 (T)
STATISTICAL TESTS
POLY 3 P=0.142 (e) (e) (e) (e) P=0.500
POLY 1.5 P=0.142 (e) (e) (e) (e) P=0.500
POLY 6 P=0.142 (e) (e) (e) (e) P=0.500
COCH-ARM / FISHERS P=0.140 (e) (e) (e) (e) P=0.500
MAX-ISO-POLY-3 P=0.041* (e) (e) (e) (e) P=0.158
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 41
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
LiverHepatodiaphragmatic Nodule
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 1/10.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 10% 0%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- 93 (T) ---
STATISTICAL TESTS
POLY 3 P=0.858N (e) (e) (e) P=0.500 (e)
POLY 1.5 P=0.858N (e) (e) (e) P=0.500 (e)
POLY 6 P=0.858N (e) (e) (e) P=0.500 (e)
COCH-ARM / FISHERS P=0.860N (e) (e) (e) P=0.500 (e)
MAX-ISO-POLY-3 P=0.193 (e) (e) (e) P=0.158 (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 42
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
LiverNecrosis Focal
LESION RATES
OVERALL (a) 1/10 (10%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/10 (0%) 0/10 (0%)
POLY-3 RATE (b) 1/10.00 0/10.00 0/10.00 1/10.00 0/10.00 0/10.00
POLY-3 PERCENT (g) 10% 0% 0% 10% 0% 0%
TERMINAL (d) 1/10 (10%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/10 (0%) 0/10 (0%)
FIRST INCIDENCE 93 (T) --- --- 93 (T) --- ---
STATISTICAL TESTS
POLY 3 P=0.550N P=0.500N P=0.500N P=0.760 P=0.500N P=0.500N
POLY 1.5 P=0.550N P=0.500N P=0.500N P=0.760 P=0.500N P=0.500N
POLY 6 P=0.550N P=0.500N P=0.500N P=0.760 P=0.500N P=0.500N
COCH-ARM / FISHERS P=0.551N P=0.500N P=0.500N P=0.763N P=0.500N P=0.500N
MAX-ISO-POLY-3 P=0.109N P=0.158N P=0.158N P=1.000 P=0.158N P=0.158N
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 43
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Liver: HepatocyteHypertrophy
LESION RATES
OVERALL (a) 0/10 (0%) 2/10 (20%) 5/10 (50%) 10/10 (100%) 10/10 (100%) 10/10 (100%)
POLY-3 RATE (b) 0/10.00 2/10.00 5/10.00 10/10.00 10/10.00 10/10.00
POLY-3 PERCENT (g) 0% 20% 50% 100% 100% 100%
TERMINAL (d) 0/10 (0%) 2/10 (20%) 5/10 (50%) 10/10 (100%) 10/10 (100%) 10/10 (100%)
FIRST INCIDENCE --- 93 (T) 93 (T) 93 (T) 93 (T) 93 (T)
STATISTICAL TESTS
POLY 3 P<0.001** P=0.227 P=0.008** P<0.001** P<0.001** P<0.001**
POLY 1.5 P<0.001** P=0.227 P=0.008** P<0.001** P<0.001** P<0.001**
POLY 6 P<0.001** P=0.227 P=0.008** P<0.001** P<0.001** P<0.001**
COCH-ARM / FISHERS P<0.001** P=0.237 P=0.016* P<0.001** P<0.001** P<0.001**
MAX-ISO-POLY-3 P<0.001** P=0.066 P<0.001** (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 44
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Liver: HepatocyteVacuolization Cytoplasmic
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 3/10 (30%) 10/10 (100%) 10/10 (100%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 3/10.00 10/10.00 10/10.00
POLY-3 PERCENT (g) 0% 0% 0% 30% 100% 100%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 3/10 (30%) 10/10 (100%) 10/10 (100%)
FIRST INCIDENCE --- --- --- 93 (T) 93 (T) 93 (T)
STATISTICAL TESTS
POLY 3 P<0.001** (e) (e) P=0.095 P<0.001** P<0.001**
POLY 1.5 P<0.001** (e) (e) P=0.095 P<0.001** P<0.001**
POLY 6 P<0.001** (e) (e) P=0.095 P<0.001** P<0.001**
COCH-ARM / FISHERS P<0.001** (e) (e) P=0.105 P<0.001** P<0.001**
MAX-ISO-POLY-3 P<0.001** (e) (e) P=0.025* (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 45
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
LungHemorrhage
LESION RATES
OVERALL (a) 0/10 (0%) 2/10 (20%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 2/10.00 0/10.00 0/10.00 1/10.00 0/10.00
POLY-3 PERCENT (g) 0% 20% 0% 0% 10% 0%
TERMINAL (d) 0/10 (0%) 2/10 (20%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/10 (0%)
FIRST INCIDENCE --- 93 (T) --- --- 93 (T) ---
STATISTICAL TESTS
POLY 3 P=0.463N P=0.227 (e) (e) P=0.500 (e)
POLY 1.5 P=0.463N P=0.227 (e) (e) P=0.500 (e)
POLY 6 P=0.463N P=0.227 (e) (e) P=0.500 (e)
COCH-ARM / FISHERS P=0.464N P=0.237 (e) (e) P=0.500 (e)
MAX-ISO-POLY-3 P=0.149N P=0.066 (e) (e) P=0.158 (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 46
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
LungInfiltration Cellular Histiocyte
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 1/10 (10%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 1/10.00 1/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 10% 10%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 1/10 (10%)
FIRST INCIDENCE --- --- --- --- 93 (T) 93 (T)
STATISTICAL TESTS
POLY 3 P=0.236 (e) (e) (e) P=0.500 P=0.500
POLY 1.5 P=0.236 (e) (e) (e) P=0.500 P=0.500
POLY 6 P=0.236 (e) (e) (e) P=0.500 P=0.500
COCH-ARM / FISHERS P=0.232 (e) (e) (e) P=0.500 P=0.500
MAX-ISO-POLY-3 P=0.109 (e) (e) (e) P=0.158 P=0.158
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 47
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
LungInflammation Chronic
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 2/10 (20%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00 2/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 20%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 2/10 (20%)
FIRST INCIDENCE --- --- --- --- --- 93 (T)
STATISTICAL TESTS
POLY 3 P=0.007** (e) (e) (e) (e) P=0.227
POLY 1.5 P=0.007** (e) (e) (e) (e) P=0.227
POLY 6 P=0.007** (e) (e) (e) (e) P=0.227
COCH-ARM / FISHERS P=0.010** (e) (e) (e) (e) P=0.237
MAX-ISO-POLY-3 P=0.005** (e) (e) (e) (e) P=0.066
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 48
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Lung: Alveolar EpitheliumHyperplasia
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 49
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Lymph Node: MediastinalHemorrhage
LESION RATES
OVERALL (a) 0/0 (0%) 0/0 (0%) 1/2 (50%) 1/1 (100%) 2/2 (100%) 0/0 (0%)
POLY-3 RATE (b) 0/0.00 0/0.00 1/2.00 1/1.00 2/2.00 0/0.00
POLY-3 PERCENT (g) 0% 0% 50% 100% 100% 0%
TERMINAL (d) 0/0 (0%) 0/0 (0%) 1/2 (50%) 1/1 (100%) 2/2 (100%) 0/0 (0%)
FIRST INCIDENCE --- --- 93 (T) 93 (T) 93 (T) ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) (e)
POLY 1.5 (e) (e) (e) (e) (e) (e)
POLY 6 (e) (e) (e) (e) (e) (e)
COCH-ARM / FISHERS P=1.000 (e) (e) (e) (e) (e)
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 50
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Lymph Node: MediastinalHyperplasia Lymphoid
LESION RATES
OVERALL (a) 0/0 (0%) 0/0 (0%) 1/2 (50%) 1/1 (100%) 2/2 (100%) 0/0 (0%)
POLY-3 RATE (b) 0/0.00 0/0.00 1/2.00 1/1.00 2/2.00 0/0.00
POLY-3 PERCENT (g) 0% 0% 50% 100% 100% 0%
TERMINAL (d) 0/0 (0%) 0/0 (0%) 1/2 (50%) 1/1 (100%) 2/2 (100%) 0/0 (0%)
FIRST INCIDENCE --- --- 93 (T) 93 (T) 93 (T) ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) (e)
POLY 1.5 (e) (e) (e) (e) (e) (e)
POLY 6 (e) (e) (e) (e) (e) (e)
COCH-ARM / FISHERS P=1.000 (e) (e) (e) (e) (e)
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 51
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Lymph Node: PancreaticHemorrhage
LESION RATES
OVERALL (a) 0/0 (0%) 0/0 (0%) 1/2 (50%) 0/1 (0%) 1/2 (50%) 0/0 (0%)
POLY-3 RATE (b) 0/0.00 0/0.00 1/2.00 0/1.00 1/2.00 0/0.00
POLY-3 PERCENT (g) 0% 0% 50% 0% 50% 0%
TERMINAL (d) 0/0 (0%) 0/0 (0%) 1/2 (50%) 0/1 (0%) 1/2 (50%) 0/0 (0%)
FIRST INCIDENCE --- --- 93 (T) --- 93 (T) ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) (e)
POLY 1.5 (e) (e) (e) (e) (e) (e)
POLY 6 (e) (e) (e) (e) (e) (e)
COCH-ARM / FISHERS P=1.000 (e) (e) (e) (e) (e)
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 52
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Lymph Node: PancreaticHyperplasia Lymphoid
LESION RATES
OVERALL (a) 0/0 (0%) 0/0 (0%) 0/2 (0%) 0/1 (0%) 0/2 (0%) 0/0 (0%)
POLY-3 RATE (b) 0/0.00 0/0.00 0/2.00 0/1.00 0/2.00 0/0.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/0 (0%) 0/0 (0%) 0/2 (0%) 0/1 (0%) 0/2 (0%) 0/0 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 53
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Lymph Node: PancreaticPigmentation
LESION RATES
OVERALL (a) 0/0 (0%) 0/0 (0%) 1/2 (50%) 0/1 (0%) 1/2 (50%) 0/0 (0%)
POLY-3 RATE (b) 0/0.00 0/0.00 1/2.00 0/1.00 1/2.00 0/0.00
POLY-3 PERCENT (g) 0% 0% 50% 0% 50% 0%
TERMINAL (d) 0/0 (0%) 0/0 (0%) 1/2 (50%) 0/1 (0%) 1/2 (50%) 0/0 (0%)
FIRST INCIDENCE --- --- 93 (T) --- 93 (T) ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) (e)
POLY 1.5 (e) (e) (e) (e) (e) (e)
POLY 6 (e) (e) (e) (e) (e) (e)
COCH-ARM / FISHERS P=1.000 (e) (e) (e) (e) (e)
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 54
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Mesentery: FatNecrosis
LESION RATES
OVERALL (a) 0/0 (0%) 1/1 (100%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%)
POLY-3 RATE (b) 0/0.00 1/1.00 0/0.00 0/0.00 0/0.00 0/0.00
POLY-3 PERCENT (g) 0% 100% 0% 0% 0% 0%
TERMINAL (d) 0/0 (0%) 1/1 (100%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%)
FIRST INCIDENCE --- 93 (T) --- --- --- ---
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) (e)
POLY 1.5 (e) (e) (e) (e) (e) (e)
POLY 6 (e) (e) (e) (e) (e) (e)
COCH-ARM / FISHERS (e) (e) (e) (e) (e) (e)
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 55
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Pituitary Gland: Pars DistalisCyst
LESION RATES
OVERALL (a) 0/9 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 1/10 (10%)
POLY-3 RATE (b) 0/9.00 0/0.00 0/0.00 0/0.00 0/0.00 1/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 10%
TERMINAL (d) 0/9 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 1/10 (10%)
FIRST INCIDENCE --- --- --- --- --- 93 (T)
STATISTICAL TESTS
POLY 3 (e) (e) (e) (e) (e) P=0.521
POLY 1.5 (e) (e) (e) (e) (e) P=0.521
POLY 6 (e) (e) (e) (e) (e) P=0.521
COCH-ARM / FISHERS P=0.440 (e) (e) (e) (e) P=0.526
MAX-ISO-POLY-3 (e) (e) (e) (e) (e) P=0.178
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 56
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Salivary GlandsNecrosis
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/0.00 0/0.00 0/0.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 0%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/10 (0%)
FIRST INCIDENCE --- --- --- --- --- ---
STATISTICAL TESTS
POLY 3 (n) (n) (n) (n) (n) (n)
POLY 1.5 (n) (n) (n) (n) (n) (n)
POLY 6 (n) (n) (n) (n) (n) (n)
COCH-ARM / FISHERS (n) (n) (n) (n) (n) (n)
MAX-ISO-POLY-3 (n) (n) (n) (n) (n) (n)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 57
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Stomach, GlandularErosion
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 3/10 (30%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 0/10.00 3/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 30%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 3/10 (30%)
FIRST INCIDENCE --- --- --- --- --- 93 (T)
STATISTICAL TESTS
POLY 3 P<0.001** (e) (e) (e) (e) P=0.095
POLY 1.5 P<0.001** (e) (e) (e) (e) P=0.095
POLY 6 P<0.001** (e) (e) (e) (e) P=0.095
COCH-ARM / FISHERS P<0.001** (e) (e) (e) (e) P=0.105
MAX-ISO-POLY-3 P<0.001** (e) (e) (e) (e) P=0.025*
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 58
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Stomach, Glandular: GlandsDilatation
LESION RATES
OVERALL (a) 0/10 (0%) 1/10 (10%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 1/10.00 0/10.00 0/10.00 1/10.00 0/10.00
POLY-3 PERCENT (g) 0% 10% 0% 0% 10% 0%
TERMINAL (d) 0/10 (0%) 1/10 (10%) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/10 (0%)
FIRST INCIDENCE --- 93 (T) --- --- 93 (T) ---
STATISTICAL TESTS
POLY 3 P=0.627N P=0.500 (e) (e) P=0.500 (e)
POLY 1.5 P=0.627N P=0.500 (e) (e) P=0.500 (e)
POLY 6 P=0.627N P=0.500 (e) (e) P=0.500 (e)
COCH-ARM / FISHERS P=0.629N P=0.500 (e) (e) P=0.500 (e)
MAX-ISO-POLY-3 P=0.270N P=0.158 (e) (e) P=0.158 (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 59
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
ThymusAtrophy
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/9 (0%) 4/10 (40%)
POLY-3 RATE (b) 0/10.00 0/10.00 0/10.00 0/10.00 0/9.00 4/10.00
POLY-3 PERCENT (g) 0% 0% 0% 0% 0% 40%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/9 (0%) 4/10 (40%)
FIRST INCIDENCE --- --- --- --- --- 93 (T)
STATISTICAL TESTS
POLY 3 P<0.001** (e) (e) (e) (e) P=0.033*
POLY 1.5 P<0.001** (e) (e) (e) (e) P=0.033*
POLY 6 P<0.001** (e) (e) (e) (e) P=0.033*
COCH-ARM / FISHERS P<0.001** (e) (e) (e) (e) P=0.043*
MAX-ISO-POLY-3 P<0.001** (e) (e) (e) (e) P=0.007**
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 60
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
ThymusHemorrhage
LESION RATES
OVERALL (a) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/10 (0%) 0/9 (0%) 0/10 (0%)
POLY-3 RATE (b) 0/10.00 0/10.00 1/10.00 0/10.00 0/9.00 0/10.00
POLY-3 PERCENT (g) 0% 0% 10% 0% 0% 0%
TERMINAL (d) 0/10 (0%) 0/10 (0%) 1/10 (10%) 0/10 (0%) 0/9 (0%) 0/10 (0%)
FIRST INCIDENCE --- --- 93 (T) --- --- ---
STATISTICAL TESTS
POLY 3 P=0.702N (e) P=0.500 (e) (e) (e)
POLY 1.5 P=0.702N (e) P=0.500 (e) (e) (e)
POLY 6 P=0.702N (e) P=0.500 (e) (e) (e)
COCH-ARM / FISHERS P=0.704N (e) P=0.500 (e) (e) (e)
MAX-ISO-POLY-3 P=0.283N (e) P=0.158 (e) (e) (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 61
DOSE 0 MG/KG 0.01 MG/KG 5 MG/KG 50 MG/KG 100 MG/KG 500 MG/KG
Thyroid Gland: FollicleHypertrophy
LESION RATES
OVERALL (a) 0/10 (0%) 0/0 (0%) 0/10 (0%) 8/10 (80%) 9/10 (90%) 10/10 (100%)
POLY-3 RATE (b) 0/10.00 0/0.00 0/10.00 8/10.00 9/10.00 10/10.00
POLY-3 PERCENT (g) 0% 0% 0% 80% 90% 100%
TERMINAL (d) 0/10 (0%) 0/0 (0%) 0/10 (0%) 8/10 (80%) 9/10 (90%) 10/10 (100%)
FIRST INCIDENCE --- --- --- 93 (T) 93 (T) 93 (T)
STATISTICAL TESTS
POLY 3 (e) (e) (e) P<0.001** P<0.001** P<0.001**
POLY 1.5 (e) (e) (e) P<0.001** P<0.001** P<0.001**
POLY 6 (e) (e) (e) P<0.001** P<0.001** P<0.001**
COCH-ARM / FISHERS P<0.001** (e) (e) P<0.001** P<0.001** P<0.001**
MAX-ISO-POLY-3 (e) (e) (e) P<0.001** P<0.001** (e)
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344/N)TERMINAL SACRIFICE AT 14 WEEKS
Females
Page 62
LEGEND
(a) Number of tumor-bearing animals/number of animals examined at site.(b) Number of tumor-bearing animals/Poly-3 number(d) Observed incidence at terminal kill.(e) Value of statistic cannot be computed.(f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group.(g) Poly-3 adjusted lifetime tumor incidence.(n) No statistics are calculated if all dose groups have fewer than two tumors.(I) Interim sacrifice(T) Terminal sacrifice# Tumor rates based on numbers of animals necropsied.* To the right of any statistical result, indicates significance at (P<=0.05).** To the right of any statistical result, indicates significance at (P<=0.01).N Indicates a negative trend for all tests
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.
*** END OF REPORT ***
Experiment Number: 20209 - 01 P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS Date Report Requested: 07/23/2014Test Type: 90-DAY Pentabromodiphenyl oxide (technical) (DE 71) Time Report Requested: 13:31:07
Route: GAVAGE CAS Number: 32534-81-9 First Dose M/F: 07/20/04 / 07/19/04Species/Strain: RATS/F 344/N Lab: SRI
Page 63
